trending Market Intelligence /marketintelligence/en/news-insights/trending/ZV-phN77WFr0M0xOL92FDw2 content esgSubNav
In This List

Protagonist Therapeutics plans common stock offering

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Protagonist Therapeutics plans common stock offering

Protagonist Therapeutics Inc. plans to sell its common stock in an underwritten public offering.

The company also plans to grant the underwriters an option to buy up to an additional 15% of the number of shares sold in the offering.

Protagonist plans to use the net proceeds to fund clinical research and development of the company's three therapeutic candidates — PTG-100, PTG-200, and PTG-300 — including the completion of ongoing clinical trials, discovery programs and platform development, and for working capital and general corporate purposes.

Leerink Partners LLC and Barclays Capital Inc. are acting as joint lead book-running managers, BMO Capital Markets Corp. and Stifel Nicolaus & Co. are acting as passive joint book-running managers, and BTIG and Nomura are acting as co-lead managers for the offering.